Fasedienol Nasal Spray for Social Anxiety Disorder
Vistagen’s fasedienol is an innovative, rapid-onset investigational pherine nasal spray in Phase 3 clinical development in the U.S. for the acute treatment of anxiety in adults with social anxiety disorder (SAD).
Anxiety disorder: Current treatments and what's on the horizon
2022年7月14日 · Aloradine is currently being developed by Pherin Pharmaceuticals as a nasal spray for the treatment of social anxiety disorder. A randomized clinical trial showed that following an intranasal application, aloradine decreased social interaction and performance anxiety to a greater degree than a placebo during a public-speaking challenge among ...
Vistagen's new drug, Fasedienol, reaches Phase 3 clinical ... - Patsnap
On August 8, 2023, Vistagen announced the positive top-line results of the PALISADE-2 Phase 3 clinical trial, which assessed the efficacy and safety of its investigational fasedienol (PH94B, Aloradine) nasal spray in adult patients with social anxiety disorder (SAD).
9 New Anxiety Medications (2018): Drugs In Clinical Trials
2018年2月17日 · Aloradine (PH94B) is a pherine or synthetic pheromone developed by Pherin Pharmaceuticals for the treatment of social anxiety disorder. It is formatted as a nasal spray to be administered on an “as-needed” basis (i.e. p.r.n.) to help reduce symptoms of social anxiety, primarily in women; it is unknown as to whether effects will also prove ...
Nasal Spray Demonstrates Ability to Reduce Social Anxiety …
2023年8月8日 · Fasedienol—a first-in-class, rapid-onset pherine nasal spray—has a novel proposed mechanism of action that regulates the olfactory-amygdala neural circuits of fear and anxiety.
VistaGen initiates second Phase 3 study of PH94B nasal ...
2021年9月13日 · VistaGen Therapeutics said that it has initiated the PALISADE-2 Phase 3 clinical trial of its PH94B aloradine nasal spray for the treatment of social anxiety disorder (SAD). The company initiated the PALISADE-1 trial of PH94B for SAD in May 2021.
VistaGen initiates Phase 3 trial of PH94B aloradine nasal
VistaGen Therapeutics has announced the initiation of the PALISADE-1 Phase 3 clinical trial of PH94B aloradine nasal spray for the treatment of social anxiety disorder (SAD). PH94B was granted Fast Track designation for that indication in December 2019.
Fasedienol - Pherin Pharmaceuticals/VistaGen Therapeutics
2024年10月7日 · Fasedienol is a vomeropherine compound, being developed by Pherin Pharmaceuticals (a subsidiary of VistaGen Therapeutics), as an intranasal spray for acute.
Fasedienol - Wikiwand
Fasedienol (INN; developmental code names PH94B and Aloradine), also known as 4-androstadienol or as 4,16-androstadien-3β-ol, is a pherine which is under development by VistaGen Therapeutics in a nasal spray formulation (PRN) for the acute treatment of social anxiety disorder.
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 …
2023年3月22日 · Fasedienol demonstrated clinically meaningful reductions in fear, anxiety and avoidance of anxiety-provoking social and performance situations in daily life, as measured by the Liebowitz Social Anxiety Scale (LSAS), building on LSAS data from a previous placebo-controlled Phase 2 study of fasedienol in SAD.
- 某些结果已被删除